A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-kB signaling in chordoma biology

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Trucco, Matteo M ^a,e   Awad, Ola ^a,f   Wilky, Breelyn A ^a   Goldstein, Seth D ^a   Huang, Ruili ^b   Walker, Robert L ^c   Shah, Preeti ^a,f   Katuri, Varalakshmi ^a   Gul, Naheed ^a   Zhu, Yuelin J ^c   McCarthy, Edward F ^d   Paz Priel, Ido ^a   Meltzer, Paul S ^c   Austin, Christopher P ^b   Xia, Menghang ^b   Loeb, David M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; I KAPPA B KINASE INHIBITOR; IMD 0354; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHORDOMA; CONTROLLED STUDY; DRUG SCREENING; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION; GENOME ANALYSIS; GENOMICS; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; MOUSE MODEL; NF KAPPAB GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; NULL ALLELE; PROTEIN EXPRESSION; SACRUM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHORDOMA; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NF-KAPPA B; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84892420483     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079950     Document Type: Article

References (29)

1. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM et al. (2007) Chordoma: the nonsarcoma primary bone tumor. Oncologist 12: 1344-1350. doi:10.1634/theoncologist.12-11-1344. PubMed: 18055855.
2. Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT et al. (2012) Chordoma: current concepts, management, and future directions. Lancet Oncol 13: e69-e76. doi:10.1016/S1470-2045(11)70337-0. PubMed: 22300861.
3. Stacchiotti S, Casali PG (2011) Systemic therapy options for unresectable and metastatic chordomas. Curr Oncol Rep 13: 323-330. doi:10.1007/s11912-011- 0176-x. PubMed: 21584646.
4. Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A et al. (2012) Phase II study of imatinib in advanced chordoma. J Clin Oncol 30: 914-920. doi:10.1200/JCO.2011.35.3656. PubMed: 22331945.
5. Dewaele B, Maggiani F, Floris G, Ampe M, Vanspauwen V et al. (2011) Frequent activation of EGFR in advanced chordomas. Clin Sarcoma Res 1: 4. doi:10.1186/2045-3329-1-4. PubMed: 22613809.
6. Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S et al. (2010) Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neuro Oncol 12: 776-789. doi:10.1093/neuonc/noq003. PubMed: 20164240.
7. Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS et al. (2006) Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 209: 157-165. doi:10.1002/path. 1969. PubMed: 16538613.
8. Presneau N, Shalaby A, Ye H, Pillay N, Halai D et al. (2011) Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J Pathol 223: 327-335. doi:10.1002/path. 2816. PubMed: 21171078.
9. Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E et al. (2009) T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet 41: 1176-1178. doi:10.1038/ng.454. PubMed: 19801981.
10. Hsu W, Mohyeldin A, Shah SR, ap Rhys CM, Johnson LF, et al. (2011) Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target. J Neurosurg 115: 760-769. doi: 10.3171/2011.5.JNS11185. PubMed: 21699479.
11. Nelson AC, Pillay N, Henderson S, Presneau N, Tirabosco R et al. (2012) An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. J Pathol 228: 274-285. doi:10.1002/path.4082. PubMed: 22847733.
12. Huang R, Southall N, Wang Y, Yasgar A, Shinn P et al. (2011) The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 3: 80ps16. PubMed: 21525397.
13. Xia M, Huang R, Sakamuru S, Alcorta D, Cho MH et al. (2013) Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther 14: 638-47. PubMed: 23792643.
14. Bitko V, Velazquez A, Yang L, Yang YC, Barik S (1997) Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa B and is inhibited by sodium salicylate and aspirin. Virology 232: 369-378. doi:10.1006/viro.1997.8582. PubMed: 9191851.
15. Morel JC, Park CC, Kumar P, Koch AE (2001) Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NFkappaB activation. Lab Invest 81: 1371-1383. doi:10.1038/labinvest.3780351. PubMed: 11598150.
16. Tsai PW, Shiah SG, Lin MT, Wu CW, Kuo ML (2003) Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. J Biol Chem 278: 5750-5759. doi:10.1074/jbc.M204863200. PubMed: 12471041.
17. Sugita S, Kohno T, Yamamoto K, Imaizumi Y, Nakajima H et al. (2002) Induction of macrophage-inflammatory protein-3alpha gene expression by TNF-dependent NF-kappaB activation. J Immunol 168: 5621-5628. PubMed: 12023359.
18. Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS et al. (2010) Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol 79: 1272-1280. doi:10.1016/j.bcp. 2009.12.021. PubMed: 20067776.
19. Tanaka A, Muto S, Konno M, Itai A, Matsuda H (2006) A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res 66: 419-426. doi:10.1158/0008-5472.CAN-05-0741. PubMed: 16397257.
20. Liu X, Nielsen GP, Rosenberg AE, Waterman PR, Yang W et al. (2012) Establishment and characterization of a novel chordoma cell line: CH22. J Orthop Res 30: 1666-1673
21. Rinner B, Froehlich EV, Buerger K, Knausz H, Lohberger B et al. (2012) Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1. Int J Oncol 40: 443-451. PubMed: 22002331.
22. Siu IM, Salmasi V, Orr BA, Zhao Q, Binder ZA et al. (2012) Establishment and characterization of a primary human chordoma xenograft model. J Neurosurg 116: 801-809. doi: 10.3171/2011.12.JNS111123. PubMed: 22283186.
23. Jambhekar NA, Rekhi B, Thorat K, Dikshit R, Agrawal M et al. (2010) Revisiting chordoma with brachyury, a "new age" marker: analysis of a validation study on 51 cases. Arch Pathol Lab Med 134: 1181-1187. PubMed: 20670140.
24. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K et al. (2006) RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66: 6512-6520. doi:10.1158/0008-5472.CAN-06-0369. PubMed: 16818622.
25. Lo PK, Lee JS, Chen H, Reisman D, Berger FG et al. (2012) Cytoplasmic mislocalization of overexpressed FOXF1 is associated with the malignancy and metastasis of colorectal adenocarcinomas. Exp Mol Pathol 94: 262-269. PubMed: 23103611.
26. Hallor KH, Staaf J, Jonsson G, Heidenblad M, Vult von Steyern F, et al. (2008) Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation. Br J Cancer 98: 434-442
27. Altomare DA, Menges CW, Pei J, Zhang L, Skele-Stump KL et al. (2009) Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proc Natl Acad Sci U S A 106: 3420-3425. doi:10.1073/pnas.0808816106. PubMed: 19223589.
28. Akers SN, Odunsi K, Karpf AR (2010) Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol 6: 717-732. doi:10.2217/fon.10.36. PubMed: 20465387.
29. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT et al. (2009) Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 27: 3154-3160. doi:10.1200/JCO.2008.20. 9890. PubMed: 19451429.